PMID: 6104255Jul 5, 1980Paper

Effect of propranolol and prazosin on blood lipids. The Oslo Study

Lancet
P LerenP G Lund-Larsen

Abstract

In 23 hypertensive men, aged 47-55, propranolol reduced serum high-density-lipoprotein (HDL) cholesterol by 13% reduced the ratio of HDL to low-density-lipoprotein (LDL)+very-low-density-lipoprotein (VLDL) cholesterol by 15%, increased total triglycerides by 24%, and increased serum uric acid by 10%. Prazosin reduced total serum cholesterol by 9%, LDL+VLDL cholesterol by 10%, and total triglycerides by 16%. These changes are statistically highly significant. On combined treatment with propranolol and prazosin HDL cholesterol was still significantly reduced but changes in other blood lipids were small and insignificant. Uric acid remained elevated. When decisions about long-term therapy are made, such metabolic effects might be of special importance.

References

Jan 1, 1976·Drugs·H J Waal-Manning
Jul 9, 1977·British Medical Journal·A NilssonB Hökfelt
Apr 15, 1978·British Medical Journal·J ShawA S Hua
Oct 1, 1976·Metabolism: Clinical and Experimental·N TanakaT Kanehisa
Aug 5, 1978·British Medical Journal·A HelgelandI Holme
Dec 1, 1978·JAMA : the Journal of the American Medical Association·W M KirkendallA Zama
Sep 10, 1977·British Medical Journal·H J Waal-Manning, F O Simpson

❮ Previous
Next ❯

Citations

Mar 1, 1993·Journal of Clinical Pharmacology·S G Carruthers
Jun 1, 1989·Cardiovascular Drugs and Therapy·M D Feher, D J Betteridge
Jan 1, 1992·European Journal of Clinical Pharmacology·T BabaT Tomiyama
Jan 1, 1983·European Journal of Clinical Pharmacology·S Rössner, L Weiner
Jan 1, 1985·European Journal of Clinical Pharmacology·M VelascoO Hernández-Pieretti
Jan 1, 1987·European Journal of Clinical Pharmacology·V A NaukkarinenS Sarna
Jan 1, 1984·European Journal of Clinical Pharmacology·L A FerraraM Mancini
Jan 1, 1981·European Journal of Clinical Pharmacology·K EliassonS Rössner
Jan 1, 1989·European Journal of Clinical Pharmacology·G Frithz
Oct 1, 1989·Cardiovascular Drugs and Therapy·O RománA Valenzuela
Oct 1, 1987·American Heart Journal·M A Weber
Jun 1, 1983·The American Journal of Cardiology·N M Kaplan
Feb 10, 1988·The American Journal of Cardiology·S H Taylor
Feb 14, 1986·The American Journal of Medicine·P Leren, A Helgeland
Jan 23, 1989·The American Journal of Medicine·H D ItskovitzJ L Mollura
Jul 30, 1986·Clinica Chimica Acta; International Journal of Clinical Chemistry·R J NorthcoteD Ballantyne
Nov 1, 1983·Progress in Cardiovascular Diseases·A V Chobanian
Mar 1, 1987·Current Problems in Cardiology·A C Cuetter, V J Ferrans
Jan 1, 1990·Pharmacology & Therapeutics·T H Pringle, J G Riddell
Feb 24, 1983·The American Journal of Cardiology·R Okun
Sep 1, 1988·Journal of the American College of Cardiology·S Arvan, B G Rueda
Dec 10, 1981·The New England Journal of Medicine·P L HooperD R Pathak
Feb 4, 1982·The New England Journal of Medicine·M F Oliver
Mar 29, 1984·The New England Journal of Medicine·W H FrishmanW T Friedewald
Mar 1, 1988·Clinical and Experimental Pharmacology & Physiology·J L ReidH L Elliott
Jun 1, 1991·Australian and New Zealand Journal of Medicine·P J Barter
Apr 17, 1982·British Medical Journal·J L DayC N Simpson

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.